ML-9 Free Base

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

ML-9 Free Base 

ML-9 (Free Base) 是 Akt 激酶的选择性强效抑制剂，可抑制肌球蛋白轻链激酶 (MLCK) 和基质相互作用分子 1 (STIM1) 的活性。 ML-9 (Free Base) 抑制 MLCK，PKA 和 PKC 活性，Ki 值分别为 4、32 和 54 μM。 ML-9 通过刺激自噬小体的形成并抑制其降解来诱导自噬 (autophagy)。

ML-9 Free Base

ML-9 Free Base Chemical Structure

CAS No. : 110448-31-2

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

ML-9 Free Base 的其他形式现货产品:

ML-9

生物活性

ML-9 (Free Base) is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity[3]. ML-9 (Free Base) inhibits inhibits MLCK, PKA and PKC activity with Ki values of 4, 32 and 54 μM, respectively[1]. ML-9 (Free Base) induces autophagy by stimulating autophagosome formation and inhibiting their degradation[3].
体外研究
(In Vitro)

ML9 (Free Base) (0-100 μM; 0-24 hours) has no reduction in cardiomyocyte viability, 50-100 μM significantly induces cell death[2].
ML9 (Free Base) (50 μM; 1-4 hours) significantly increases cleaved caspase-3 levels, decreased STIM1 protein levels by about 42%[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: Neonatal rat ventricular myocytes (NRVM) cells
Concentration: 0, 10, 50 and 100 μM
Incubation Time: 0, 1, 4, 8 and 24 hours
Result: Decreased cell viability at 50–100 μM concentration.

Apoptosis Analysis[1]

Cell Line: Neonatal rat ventricular myocytes (NRVM) cells
Concentration: 50 μM
Incubation Time: 0, 1, 4, 8 hours
Result: Induced cardiomyocyte death through necrosis and apoptosis.

分子量

324.83

Formula

C15H17ClN2O2S
CAS 号

110448-31-2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Ito S, et al. ML-9, a myosin light chain kinase inhibitor, reduces intracellular Ca2+ concentration in guinea pig trachealis.Eur J Pharmacol. 2004 Feb 23;486(3):325-33.

    [2]. Shaikh S, et al. The STIM1 inhibitor ML9 disrupts basal autophagy in cardiomyocytes by decreasing lysosome content.Toxicol In Vitro. 2018 Apr;48:121-127.

    [3]. Kondratskyi A1, et al.Identification of ML-9 as a lysosomotropic agent targeting autophagy and cell death.Cell Death Dis. 2014 Apr 24;5:e1193.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务